Research highlight: EGFR mutations in NSCLC

 

This month, the Genetics Journal Club features a double-blind randomized clinical trial which compared the use of a third-generation irreversible EGFR-TKI (osimertinib) versus standard therapy (gefitinib or erlotinib) to treat non small-cell lung cancer.  You can read the results of this study in the New England Journal of Medicine.

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., … & Okamoto, I. (2017). Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine.

To learn more about EGFR mutations in non small-cell lung cancer, explore additional readings from Himmelfarb Library’s full-text collection:

Explore more of Himmelfarb Library’s genetics collection by checking out:

This entry was posted in E-Texts, Journals. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s